Christine M Groth1, Nicole M Acquisto2, Colin Wright3,4, Mark Marinescu5, Scott McNitt6, Ilan Goldenberg6, Scott J Cameron5,7. 1. Department of Pharmacy, University of Rochester Medical Center, Rochester, New York, USA. 2. Department of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, New York, USA. 3. Department of Medicine, Highland Hospital, Rochester, New York, USA. 4. Department of Interventional Cardiology, St. Elizabeth Hospital, Utica, New York, USA. 5. Department of Medicine, Cardiology, University of Rochester Medical Center, Rochester, New York, USA. 6. Department of Medicine, Cardiology Heart Research, University of Rochester Medical Center, Rochester, New York, USA. 7. Heart, Thoracic, and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Abstract
Introduction: Pulmonary embolism response teams (PERTs) were developed to assist with diagnosis, risk stratification, and management of intermediate and high-risk pulmonary embolism (PE) and have been shown to reduce 90-day mortality. The pharmacist's role on the PERT is not well defined. Objectives: Describe the pharmacist's role as a PERT member and determine if pharmacists can improve time to anticoagulation and promote use of low molecular weight heparin (LMWH) instead of unfractionated heparin (UFH). Methods: A retrospective, observational study of adult patients with massive or submassive PE between January 2014 and May 2020. Patient demographics, clinical variables, anticoagulation treatment/timing, and pharmacist activities during PERT response were evaluated. Patients were divided into three groups for comparisons (pre-PERT vs post-PERT with a pharmacist vs post-PERT without a pharmacist). Wilcoxon rank-sum or Kruskal-Wallis test and chi-squared analysis were used for continuous and categorical data, respectively. Results: A total of 573 patients were included (mean age 63.2 ± 15.6 years, 54% male, 78% submassive PE); 137 in the pre-PERT and 436 in the post-PERT groups. Within the post-PERT group, 305 patients (70%) had a pharmacist as a member of the PERT, of which 222 (73%) had a documented pharmacotherapy-related intervention/activity. Most (n = 178, 58%) involved a pharmacist facilitating ordering/administration of an anticoagulant/thrombolytic. Median time from diagnosis to anticoagulation was significantly reduced in the post-PERT groups (pre-PERT: 104 minutes [IQR 124.5], post-PERT with a pharmacist: 63 minutes [IQR 84], post-PERT without a pharmacist: 75.5 minutes [IQR 113], P = .0001). More patients in the post-PERT groups received LMWH compared to UFH when a pharmacist was involved vs without a pharmacist (69.5% vs 53.3%, P = .0019) and major bleeding events were reduced (pre-PERT: 14.6%, post-PERT with a pharmacist: 4.6%, and post-PERT without a pharmacist: 9.9%, P = .0013). Conclusion: Pharmacists have an active role on the PERT and their involvement was associated with a shorter diagnosis to anticoagulation time, increased LMWH use, and fewer major bleeding events.
Introduction: Pulmonary embolism response teams (PERTs) were developed to assist with diagnosis, risk stratification, and management of intermediate and high-risk pulmonary embolism (PE) and have been shown to reduce 90-day mortality. The pharmacist's role on the PERT is not well defined. Objectives: Describe the pharmacist's role as a PERT member and determine if pharmacists can improve time to anticoagulation and promote use of low molecular weight heparin (LMWH) instead of unfractionated heparin (UFH). Methods: A retrospective, observational study of adult patients with massive or submassive PE between January 2014 and May 2020. Patient demographics, clinical variables, anticoagulation treatment/timing, and pharmacist activities during PERT response were evaluated. Patients were divided into three groups for comparisons (pre-PERT vs post-PERT with a pharmacist vs post-PERT without a pharmacist). Wilcoxon rank-sum or Kruskal-Wallis test and chi-squared analysis were used for continuous and categorical data, respectively. Results: A total of 573 patients were included (mean age 63.2 ± 15.6 years, 54% male, 78% submassive PE); 137 in the pre-PERT and 436 in the post-PERT groups. Within the post-PERT group, 305 patients (70%) had a pharmacist as a member of the PERT, of which 222 (73%) had a documented pharmacotherapy-related intervention/activity. Most (n = 178, 58%) involved a pharmacist facilitating ordering/administration of an anticoagulant/thrombolytic. Median time from diagnosis to anticoagulation was significantly reduced in the post-PERT groups (pre-PERT: 104 minutes [IQR 124.5], post-PERT with a pharmacist: 63 minutes [IQR 84], post-PERT without a pharmacist: 75.5 minutes [IQR 113], P = .0001). More patients in the post-PERT groups received LMWH compared to UFH when a pharmacist was involved vs without a pharmacist (69.5% vs 53.3%, P = .0019) and major bleeding events were reduced (pre-PERT: 14.6%, post-PERT with a pharmacist: 4.6%, and post-PERT without a pharmacist: 9.9%, P = .0013). Conclusion: Pharmacists have an active role on the PERT and their involvement was associated with a shorter diagnosis to anticoagulation time, increased LMWH use, and fewer major bleeding events.
Authors: Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Jacqueline E Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao Journal: Circulation Date: 2012-12-17 Impact factor: 29.690
Authors: Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori Journal: Eur Heart J Date: 2014-08-29 Impact factor: 29.983
Authors: Colin Wright; Ayman Elbadawi; Yu Lin Chen; Dhwani Patel; Justin Mazzillo; Nicole Acquisto; Christine Groth; Joseph Van Galen; Joseph Delehanty; Anthony Pietropaoli; David Trawick; R James White; Pamela Cameron; Igor Gosev; Bryan Barrus; Neil G Kumar; Scott J Cameron Journal: J Thromb Thrombolysis Date: 2019-08 Impact factor: 2.300
Authors: Nicole M Acquisto; Daniel P Hays; Rollin J Terry Fairbanks; Manish N Shah; Joseph Delehanty; Flavia Nobay; Joseph Guido; Curtis E Haas Journal: J Emerg Med Date: 2010-09-02 Impact factor: 1.484
Authors: Colin Wright; Ilan Goldenberg; Susan Schleede; Scott McNitt; Igor Gosev; Ayman Elbadawi; Anthony Pietropaoli; Bryan Barrus; Yu Lin Chen; Justin Mazzillo; Nicole M Acquisto; Joseph Van Galen; Annelise Hamer; Mark Marinescu; Joseph Delehanty; Scott J Cameron Journal: Am J Cardiol Date: 2021-12-15 Impact factor: 2.778
Authors: Lukas Hobohm; Ioannis T Farmakis; Karsten Keller; Barbara Scibior; Anna C Mavromanoli; Ingo Sagoschen; Thomas Münzel; Ingo Ahrens; Stavros Konstantinides Journal: Clin Res Cardiol Date: 2022-08-17 Impact factor: 6.138